Assessing Colonic Folate Absorption & Metabolism
Factors Affecting Colonic Folate Absorption and Metabolism in Humans
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males >18 years old and <75 years old;
- Females who are pre-menopausal that have had a hysterectomy or tubal ligation, post-menopausal (at least 1 year) and <75 years old;
- Describe themselves as generally healthy.
- Recommended to have a colonoscopy examination by their Doctor
Exclusion Criteria:
- They have a history of gastrointestinal disease (such as Crohn's disease, ulcerative colitis, celiac disease) and/ or gastrointestinal cancers;
- They have had a previous colon resection;
- They are regularly using medications that may affect gastrointestinal pH or folate metabolism (e.g. proton pump inhibitors, phenytoin, phenobarbital, primidone, or have used oral antibiotics within the last 2 weeks);
- On a regular basis they consume >2 alcoholic drinks/day for women or >3/day for men;
- They are currently smokers;
- They are folic acid supplement users or have used folic acid supplements or multivitamins containing folic acid in the last 4 months;
- They have a bleeding disorder (such as hemophilia)
- They are unlikely able to discontinue anti-coagulant therapy prior to colonoscopy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Folic Acid supplementation
Participants receive an adult multivitamin supplement along with a folic acid supplement
|
Participants receive a 400 microgram Folic Acid supplement
Participants will receive an adult multivitamin supplement
|
|
Placebo Comparator: No supplementation
Participants only receive an adult multivitamin supplement
|
Participants will receive an adult multivitamin supplement
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Colonic folate levels
Time Frame: 4 months
|
Evaluate the impact of 0 and 400 µg supplemental folic acid on total folate concentrations within the colonic mucosa by measuring folate levels
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PCFT
Time Frame: 4 months
|
Evaluate the impact of 0 and 400 µg supplemental folic acid on the regulation of PCFT in the ileum and colon by assessing the expression of mRNA transcripts and proteins
|
4 months
|
|
RFC
Time Frame: 4 months
|
Evaluate the impact of 0 and 400 µg supplemental folic acid on the regulation of RFC in the ileum and colon by assessing the expression of mRNA transcripts and proteins
|
4 months
|
|
GCPII
Time Frame: 4 months
|
Determine the degree to which GCPII is present in the lumen of the ileum and colon by quantifying enzyme activity and expression of mRNA transcripts and proteins
|
4 months
|
|
GGH
Time Frame: 4 months
|
Determine the degree to which GGH is present in the lumen of the ileum and colon by quantifying enzyme activity and expression of mRNA transcripts and proteins
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998. Available from http://www.ncbi.nlm.nih.gov/books/NBK114310/
- Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J. 2011 Aug 1;437(3):357-72. doi: 10.1042/BJ20110326.
- Mason JB, Tang SY. Folate status and colorectal cancer risk: A 2016 update. Mol Aspects Med. 2017 Feb;53:73-79. doi: 10.1016/j.mam.2016.11.010. Epub 2016 Nov 24.
- De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernandez B, Lee NS, Niyonsenga T. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med. 2007 Jul 12;357(2):135-42. doi: 10.1056/NEJMoa067103.
- Lakoff A, Fazili Z, Aufreiter S, Pfeiffer CM, Connolly B, Gregory JF 3rd, Pencharz PB, O'Connor DL. Folate is absorbed across the human colon: evidence by using enteric-coated caplets containing 13C-labeled [6S]-5-formyltetrahydrofolate. Am J Clin Nutr. 2014 Nov;100(5):1278-86. doi: 10.3945/ajcn.114.091785. Epub 2014 Sep 3.
- Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006 Dec 1;127(5):917-28. doi: 10.1016/j.cell.2006.09.041.
- Dudeja PK, Torania SA, Said HM. Evidence for the existence of a carrier-mediated folate uptake mechanism in human colonic luminal membranes. Am J Physiol. 1997 Jun;272(6 Pt 1):G1408-15. doi: 10.1152/ajpgi.1997.272.6.G1408.
- Kumar CK, Moyer MP, Dudeja PK, Said HM. A protein-tyrosine kinase-regulated, pH-dependent, carrier-mediated uptake system for folate in human normal colonic epithelial cell line NCM460. J Biol Chem. 1997 Mar 7;272(10):6226-31. doi: 10.1074/jbc.272.10.6226.
- Paniz C, Bertinato JF, Lucena MR, De Carli E, Amorim PMDS, Gomes GW, Palchetti CZ, Figueiredo MS, Pfeiffer CM, Fazili Z, Green R, Guerra-Shinohara EM. A Daily Dose of 5 mg Folic Acid for 90 Days Is Associated with Increased Serum Unmetabolized Folic Acid and Reduced Natural Killer Cell Cytotoxicity in Healthy Brazilian Adults. J Nutr. 2017 Sep;147(9):1677-1685. doi: 10.3945/jn.117.247445. Epub 2017 Jul 19.
- Chakraborty H, Nyarko KA, Goco N, Moore J, Moretti-Ferreira D, Murray JC, Wehby GL. Folic Acid Fortification and Women's Folate Levels in Selected Communities in Brazil - A First Look. Int J Vitam Nutr Res. 2014;84(5-6):286-94. doi: 10.1024/0300-9831/a000215.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1000059584
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Folate
-
NCT06641245Not yet recruitingPregnancy | Folate | Folate Bioavailability | Clinical Trials
-
NCT00130585CompletedHealthy | Folate Bioavailability
-
NCT01105351Completedthe Effect of MTHFR C677T on Folate Metabolism
-
NCT01180933CompletedPerinatal DHA and Folate Status | Neurological Development
-
NCT04095052Active, not recruitingFolate Deficiency
-
NCT05865015CompletedBody Weight | IVF | Nutrient Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Folate Deficiency Anemia
-
NCT05792241CompletedFolate Deficiency | Iodine Deficiency | Anemia, Macrocytic | Anemia Deficiency | Salt Intake
-
NCT04974138RecruitingHypertension | MTHFR 677 CC or CT Genotype | Elevated Plasma Homocysteine (Hcy≥10µmol/L) | Insufficient Plasma Folate Levels (<12ng/mL)
Clinical Trials on Folic Acid supplementation
-
NCT07540130Active, not recruitingPregnant Women | Pregnant Women and Their Offspring
-
NCT05097365Enrolling by invitationOverweight and Obesity | Lupus Erythematosus
-
NCT02235948UnknownArsenic Poisoning | Toxic Effect of Arsenic and Its Compounds
-
NCT00111267CompletedCognitive Decline | Cognitive Symptoms
-
NCT03438942Completed
-
NCT04850820CompletedExercise | Metabolism | Amino Acids, Essential
-
NCT01931293UnknownAtrophic Glossitis, Burning Mouth Syndrome
-
NCT06815315Completed
-
NCT04277364UnknownHypertrophy | Muscle Strength
-
NCT04531410Completed